Technical Analysis for ERAS - Erasca, Inc

Grade Last Price % Change Price Change
F 11.635 2.96% 0.34
ERAS closed down 7.15 percent on Wednesday, January 19, 2022, on 1.52 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical ERAS trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 2.96%
New 52 Week Low Weakness 2.96%
Stochastic Reached Oversold Weakness 2.96%
Wide Bands Range Expansion 2.96%
Below Lower BB Weakness 2.96%
Down 3 Days in a Row Weakness 2.96%
Down 4 Days in a Row Weakness 2.96%
Lower Bollinger Band Touch Weakness 2.96%
Oversold Stochastic Weakness 2.96%
Down 3 Days in a Row Weakness -4.40%
Older End-of-Day Signals for ERAS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
5x Volume Pace about 2 hours ago
2x Volume Pace about 3 hours ago
3x Volume Pace about 3 hours ago
Up 5% about 3 hours ago
1.5x Volume Pace about 3 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acute Myeloid Leukemia Enzymes Colorectal Cancer Tyrosine Kinase Receptors Oncogenes Bemcentinib Nsclc Non Small Cell Lung Carcinoma Metastatic Solid Tumors Ptpn11 Ras Gtpase

Is ERAS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 24.47
52 Week Low 11.0
Average Volume 460,163
200-Day Moving Average 0.00
50-Day Moving Average 15.10
20-Day Moving Average 13.64
10-Day Moving Average 12.70
Average True Range 1.36
ADX 17.7
+DI 15.56
-DI 25.37
Chandelier Exit (Long, 3 ATRs) 11.93
Chandelier Exit (Short, 3 ATRs) 15.08
Upper Bollinger Bands 15.97
Lower Bollinger Band 11.31
Percent B (%b) 0.0
BandWidth 34.11
MACD Line -0.79
MACD Signal Line -0.65
MACD Histogram -0.1358
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.04
Resistance 3 (R3) 14.24 13.54 13.58
Resistance 2 (R2) 13.54 12.84 13.43 13.43
Resistance 1 (R1) 12.42 12.41 12.06 12.21 13.28
Pivot Point 11.71 11.71 11.53 11.61 11.71
Support 1 (S1) 10.59 11.01 10.24 10.39 9.32
Support 2 (S2) 9.88 10.58 9.78 9.17
Support 3 (S3) 8.76 9.88 9.02
Support 4 (S4) 8.56